BR112023017371A2 - Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2 - Google Patents

Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2

Info

Publication number
BR112023017371A2
BR112023017371A2 BR112023017371A BR112023017371A BR112023017371A2 BR 112023017371 A2 BR112023017371 A2 BR 112023017371A2 BR 112023017371 A BR112023017371 A BR 112023017371A BR 112023017371 A BR112023017371 A BR 112023017371A BR 112023017371 A2 BR112023017371 A2 BR 112023017371A2
Authority
BR
Brazil
Prior art keywords
bcl
inhibitors
nitrophenyl
acetamide
sulfonyl
Prior art date
Application number
BR112023017371A
Other languages
English (en)
Inventor
Vasilievich Ivachtchenko Alexandre
Alexei Pushechnikov
Andrew Orry
Nikolay Savchuk
Chun-Hung LAM Polo
Ruben Abagyan
Zenonovich PARCHINSKY Vladislav
Volodymyr Kysil
Original Assignee
Eil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eil Therapeutics Inc filed Critical Eil Therapeutics Inc
Publication of BR112023017371A2 publication Critical patent/BR112023017371A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2. a presente invenção é genericamente direcionada a inibidores de proteínas bcl-2 úteis no tratamento de doenças e distúrbios modulados pela dita enzima e que têm a fórmula (i).
BR112023017371A 2021-03-19 2022-03-18 Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2 BR112023017371A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163163326P 2021-03-19 2021-03-19
PCT/US2022/020986 WO2022198069A1 (en) 2021-03-19 2022-03-18 Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
BR112023017371A2 true BR112023017371A2 (pt) 2023-10-03

Family

ID=83321213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017371A BR112023017371A2 (pt) 2021-03-19 2022-03-18 Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2

Country Status (11)

Country Link
US (1) US11834450B2 (pt)
EP (1) EP4308092A1 (pt)
JP (1) JP2024510434A (pt)
KR (1) KR20230159524A (pt)
CN (1) CN117642157A (pt)
AR (1) AR125046A1 (pt)
AU (1) AU2022240765A1 (pt)
BR (1) BR112023017371A2 (pt)
CA (1) CA3211639A1 (pt)
MX (1) MX2023011000A (pt)
WO (1) WO2022198069A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270660A (zh) * 2023-03-30 2023-06-23 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02205B (me) * 2009-05-26 2016-02-20 Abbvie Bahamas Ltd INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105218483A (zh) 2010-03-25 2016-01-06 Abbvie公司 用于治疗癌症和免疫以及自身免疫性疾病的细胞凋亡诱导剂
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US10195213B2 (en) * 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN117430601A (zh) * 2018-04-29 2024-01-23 百济神州有限公司 Bcl-2抑制剂

Also Published As

Publication number Publication date
EP4308092A1 (en) 2024-01-24
JP2024510434A (ja) 2024-03-07
CN117642157A (zh) 2024-03-01
CA3211639A1 (en) 2022-09-22
AR125046A1 (es) 2023-05-31
MX2023011000A (es) 2023-09-28
US11834450B2 (en) 2023-12-05
AU2022240765A1 (en) 2023-09-07
WO2022198069A1 (en) 2022-09-22
US20220306625A1 (en) 2022-09-29
KR20230159524A (ko) 2023-11-21

Similar Documents

Publication Publication Date Title
CO2023013356A2 (es) Compuestos para la inhibición de nlrp3 y usos de estos
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CO2018010504A2 (es) Inhibidores del enlace proteína-proteína de wdr5
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
MA38483A1 (fr) Inhibiteurs de l'ido
BR112021020520A2 (pt) Inibidores da di-hidro-orotato desidrogenase
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
BR122020016659B8 (pt) moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
CO2022009438A2 (es) Fluoroalquil-oxadiazoles y sus usos
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200401270A1 (ru) Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
BR112023017371A2 (pt) Compostos que têm ((3-nitrofenil)sulfonil)acetamida como inibidores de bcl-2
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
BR112022014949A2 (pt) Compostos e usos dos mesmos
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022015109A2 (pt) Compostos e usos dos mesmos
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
BR112023017344A2 (pt) Compostos que têm tetra-hidroindolizina-1-carboxamida como inibidores de bcl-2